The disclosure relates to combination therapies using anti-CD38 antibodies. Specifically, the disclosure provides methods of treating a subject having acute lymphoblastic leukemia (ALL), using an anti-CD38 antibody, wherein the anti-CD38 antibody induces in vitro killing of ALL cells by antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement dependent cytotoxicity (CDC), apoptosis, or in vitro modulation of CD38 enzymatic activity.La présente invention concerne des polythérapies avec des anticorps anti-CD38.
